Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randy Lieberman

Clinical Cardiac Electrophysiology Detroit, MI Medical Doctor

NPI 1679513543 CMS profile 303203

4201 Saint Antoine St Ste 7B, Detroit, MI 48201

Open in the dashboard

General payments

$1,184,124

1,317 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$70,832 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Randy Lieberman of Detroit, MI is reported in the CMS Open Payments database as having received $1,184,124 across 1,317 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $70,832 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,405 105
2024 General $84,307 126
2023 General $157,539 206
2022 General $273,144 264
2021 General $243,852 205
2020 General $218,906 188
2019 General $172,972 223

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randy Lieberman
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Randy Lieberman were reported at $33,405. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Randy Lieberman Clinical Cardiac Electrophysiology median Middle half National median
2019 $172,972 $2,361 $585–$8,260 $163
2020 $218,906 $993 $247–$4,351 $114
2021 $243,852 $1,185 $326–$4,739 $132
2022 $273,144 $2,073 $554–$6,789 $149
2023 $157,539 $2,568 $759–$8,159 $160
2024 $84,307 $2,557 $703–$7,403 $164
2025 $33,405 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $384,336 362 payments
  2. Sanofi-Aventis U.S. LLC $373,944 210 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $100,233 87 payments
  4. Amgen Inc. $80,034 179 payments
  5. Esperion Therapeutics, Inc. $51,882 38 payments
  6. Merck Sharp & Dohme Corporation $49,830 49 payments
  7. Pfizer Inc. $45,731 77 payments
  8. Lilly USA, LLC $29,022 26 payments
  9. Novo Nordisk Inc $25,075 18 payments
  10. Aziyo Biologics, Inc. $15,194 17 payments
  11. Other $28,844 254 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,052,482 367 payments
  2. Travel and Lodging $52,879 250 payments
  3. Consulting Fee $37,585 15 payments
  4. Food and Beverage $26,696 678 payments
  5. Honoraria $14,482 7 payments
Products named General payments · program years 2019–2025
  1. XARELTO $380,070 362 payments
  2. MULTAQ Cardiology/Vascular Diseases $208,488 108 payments
  3. MULTAQ Cardiology/Vascular Diseases $152,082 81 payments
  4. JARDIANCE $93,204 77 payments
  5. Repatha $78,198 157 payments
  6. VERQUVO Cardiovascular $54,607 54 payments
  7. NEXLETOL $51,882 38 payments
  8. NEXLIZET $51,882 38 payments
  9. ELIQUIS $45,627 72 payments
  10. VERQUVO Cardiovascular $45,037 43 payments
  11. Other $111,210 394 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

928

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$542,631

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

55.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 105 $123,133
Jardiance Empagliflozin Brand 94 $102,562
Xarelto Rivaroxaban Brand 59 $73,368
Eliquis Apixaban Brand 64 $66,598
Multaq Dronedarone Hcl Brand 53 $55,184
Verquvo Vericiguat Brand 29 $46,533
Repatha Sureclick Evolocumab Brand 32 $28,635
Ozempic Semaglutide Brand 19 $17,872
Farxiga Dapagliflozin Propanediol Brand 17 $12,724
Spiriva Handihaler Tiotropium Bromide Brand 11 $5,669

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$96,674

Medicare's payments for the services billed

Medicare patients

272

Average age 74

Services billed

650

123 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 70%
Atrial fibrillation 69%
Arthritis 55%
Diabetes 51%
Chronic kidney disease 48%
COPD 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MULTAQ
$37,933 53 —
Repatha
$16,231 32 —
JARDIANCE
$14,616 94 —
XARELTO
$6,864 59 —
VERQUVO
$4,777 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

1,317 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record